Agfa HealthCare’s IMPAX HeartStation enables quick diagnosis of 15-lead ECG studies in comparison with 12-lead ECG research at Western Maryland Regional INFIRMARY Agfa HealthCare, a leading provider of diagnostic health care and imaging It all solutions, today announces that Western Maryland Regional Medical Center’s recent update to the newest version of IMPAX HeartStation ECG Management Program has helped enable the fast analysis and treatment of sufferers with posterior wall heart attacks. The Cumberland-based hospital is using the lately released features of IMPAX HeartStation to digitally review and archive 15-lead ECG studies online pharmacy reviews . Compared to more commonly found 12-lead ECG equipment, 15-lead ECG provides more full data for detecting heart episodes in the posterior and right ventricle walls.
Vioxx, Celebrex and Bextra hit the market in the late 1990s & 2001, as a breakthrough class of medications for arthritis that could help avoid ulcers and other digestive ailments associated with medicines such as for example aspirin. With their debut coinciding with a surge in advertising aimed straight at consumers, they and Bextra, that was approved in 2001, became probably the most heavily promoted drug classes quickly. These drugs have been linked to an elevated risk of heart episodes and strokes and several people were uncovered unnecessarily to those risks. Intense marketing helped make them some of the most widely prescribed medicines in the United States and a severe lesson has been learned.